UA87487C2 - Полиморфные формы габоксадола, агониста gabaа, способ их получения и применение - Google Patents

Полиморфные формы габоксадола, агониста gabaа, способ их получения и применение

Info

Publication number
UA87487C2
UA87487C2 UAA200609410A UAA200609410A UA87487C2 UA 87487 C2 UA87487 C2 UA 87487C2 UA A200609410 A UAA200609410 A UA A200609410A UA A200609410 A UAA200609410 A UA A200609410A UA 87487 C2 UA87487 C2 UA 87487C2
Authority
UA
Ukraine
Prior art keywords
preparation
polymorphic forms
gabaa agonist
gabaa
agonist
Prior art date
Application number
UAA200609410A
Other languages
English (en)
Ukrainian (uk)
Inventor
Винсент Бретт Купер
Original Assignee
Х.Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA87487(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х.Лундбекк А/С filed Critical Х.Лундбекк А/С
Publication of UA87487C2 publication Critical patent/UA87487C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В заявке описаны два новых кристаллических моногидрата и два новых кристаллических ангидрата габоксадола, а также способы их приготовления.
UAA200609410A 2004-01-30 2005-01-28 Полиморфные формы габоксадола, агониста gabaа, способ их получения и применение UA87487C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
UA87487C2 true UA87487C2 (ru) 2009-07-27

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200609410A UA87487C2 (ru) 2004-01-30 2005-01-28 Полиморфные формы габоксадола, агониста gabaа, способ их получения и применение

Country Status (35)

Country Link
US (2) US7262300B2 (ru)
EP (2) EP1713813B1 (ru)
JP (1) JP4917440B2 (ru)
KR (1) KR101210361B1 (ru)
CN (1) CN1914212B (ru)
AR (1) AR047511A1 (ru)
AT (1) ATE414088T1 (ru)
AU (1) AU2005209473B2 (ru)
BR (1) BRPI0506858A (ru)
CA (1) CA2554536C (ru)
CO (1) CO5700743A2 (ru)
CY (1) CY1108647T1 (ru)
DE (1) DE602005010975D1 (ru)
DK (1) DK1713813T3 (ru)
DO (1) DOP2005000013A (ru)
EA (1) EA009413B1 (ru)
EC (1) ECSP066735A (ru)
ES (1) ES2314613T3 (ru)
GB (2) GB0402118D0 (ru)
HK (1) HK1096547A1 (ru)
HR (1) HRP20080614T3 (ru)
IL (1) IL176863A0 (ru)
MA (1) MA28364A1 (ru)
MX (1) MXPA06008595A (ru)
MY (1) MY139525A (ru)
NO (1) NO20063843L (ru)
NZ (1) NZ548191A (ru)
PE (1) PE20050769A1 (ru)
PL (1) PL1713813T3 (ru)
PT (1) PT1713813E (ru)
SI (1) SI1713813T1 (ru)
TW (1) TWI345972B (ru)
UA (1) UA87487C2 (ru)
WO (1) WO2005073237A2 (ru)
ZA (1) ZA200605307B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP2292222A1 (en) * 2005-01-28 2011-03-09 H. Lundbeck A/S Polymorphic Forms of a GABAA Agonist
CN101309667A (zh) 2005-09-28 2008-11-19 奥里斯医学股份有限公司 治疗内耳疾病的药用合成物
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
JP2018520189A (ja) * 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
EP4153549A2 (en) 2020-05-20 2023-03-29 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (ru) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводная кристаллическая форма гидрохлорида r(-)-n-(4,4-ди(3-метилтиен-2-ил)бут-3-енил) нипекотиновой кислоты
CA2385749A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
EP1399138B1 (de) 2001-05-18 2006-02-08 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
CA2447603A1 (en) 2001-05-21 2002-11-28 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
PL1641456T3 (pl) 2003-06-25 2010-08-31 H Lundbeck As Gaboksadol do leczenia depresji i innych zaburzeń afektywnych
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06015196A (es) 2004-06-29 2007-03-15 Lundbeck & Co As H Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP2292222A1 (en) * 2005-01-28 2011-03-09 H. Lundbeck A/S Polymorphic Forms of a GABAA Agonist
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL

Also Published As

Publication number Publication date
CA2554536C (en) 2012-09-18
TW200534856A (en) 2005-11-01
HK1096547A1 (en) 2007-06-01
NO20063843L (no) 2006-08-29
PE20050769A1 (es) 2005-10-04
US8236958B2 (en) 2012-08-07
SI1713813T1 (sl) 2009-02-28
GB0402118D0 (en) 2004-03-03
HRP20080614T3 (en) 2009-01-31
AR047511A1 (es) 2006-01-25
WO2005073237A2 (en) 2005-08-11
PL1713813T3 (pl) 2009-04-30
DK1713813T3 (da) 2009-02-16
EA009413B1 (ru) 2007-12-28
MY139525A (en) 2009-10-30
MXPA06008595A (es) 2006-08-28
NZ548191A (en) 2010-04-30
ZA200605307B (en) 2007-11-28
EA200601404A1 (ru) 2006-12-29
EP1713813A2 (en) 2006-10-25
AU2005209473B2 (en) 2010-03-04
KR101210361B1 (ko) 2012-12-10
DOP2005000013A (es) 2005-08-15
CA2554536A1 (en) 2005-08-11
AU2005209473A1 (en) 2005-08-11
JP4917440B2 (ja) 2012-04-18
CN1914212B (zh) 2010-10-06
BRPI0506858A (pt) 2007-05-29
TWI345972B (en) 2011-08-01
MA28364A1 (fr) 2006-12-01
GB2410434A (en) 2005-08-03
PT1713813E (pt) 2008-12-26
US20050171142A1 (en) 2005-08-04
IL176863A0 (en) 2006-10-31
US7262300B2 (en) 2007-08-28
CY1108647T1 (el) 2014-04-09
DE602005010975D1 (de) 2008-12-24
US20070259912A1 (en) 2007-11-08
ES2314613T3 (es) 2009-03-16
CN1914212A (zh) 2007-02-14
ECSP066735A (es) 2006-10-31
ATE414088T1 (de) 2008-11-15
EP2042505A1 (en) 2009-04-01
EP1713813B1 (en) 2008-11-12
CO5700743A2 (es) 2006-11-30
GB0501847D0 (en) 2005-03-09
KR20070007070A (ko) 2007-01-12
JP2007519697A (ja) 2007-07-19
WO2005073237A3 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
UA87487C2 (ru) Полиморфные формы габоксадола, агониста gabaа, способ их получения и применение
MX2009011255A (es) Proceso para preparar capecitabina.
HK1088597A1 (en) Method for the production of substituted 3-aryl-butyl amine compounds
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
MY145604A (en) Process for the preparation of chiral 8-(3-aminopiperidine-1-yl)-xanthines
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
SG166091A1 (en) Method for producing isocyanates
WO2008066558A3 (en) Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
EP1720993B8 (en) Method for producing l-threonine using bacteria belonging to the genus escherichia
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
WO2007081907A3 (en) Crystalline forms of dolasetron base and processes for preparation thereof
EP1781677A4 (en) PROCESS FOR PREPARING A D-ERYTHRO-2,2-DIFLUORO-2-DEOXY-1-OXORIBOSE DERIVATIVE
HK1122743A1 (en) Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin- related compounds and a disaccharide for treating proliferative diseases
TW200617011A (en) Process for preparing quinoline compounds and products obtained therefrom
TW200616633A (en) CCI-779 derivatives and methods of making same
UA87710C2 (ru) Способ получения производных [1,4,5]-оксадиазепина
AU2003300324A1 (en) Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
AU2008306604A8 (en) Process for the preparation of zolmitriptan, salts and solvates thereof
SG161305A1 (en) Process for the separation of probucol derivatives
WO2009027766A3 (en) New crystalline solid forms of o-desvenlafaxine base
WO2009042853A3 (en) Fluorinated oxy-carboxylic acids, derivatives, and methods of preparation
AU2003294161A1 (en) An improved process for the preparation of cefoxitin
ZA200706624B (en) Reactive dyestuffs, method for the production thereof and use of the same
ZA200707324B (en) Mixture of water-soluble fibre-reactive dyes, method for the production thereof, and use of the same
ZA200606861B (en) Improved process for the preparation of 9,11epoxy steroids